Swiss Biotech Center offers capabilities of development and manufacturing of biopharmaceuticals on mammalian expression systems up to clinical batches under cGMP quality standards. We deliver bulks of low bioburden active pharmaceutical ingredients ready for formulation and Fill&Finish. Our state-of-the-art facility is operating with single-use technologies at each step of the process allowing an outstanding flexibility and rapidity, with a maximum batch size of 200L fed-batch. In addition to that, Swiss Biotech Center gathers a strong network of partners allowing to embark on a full development of biopharmaceuticals, from the DNA sequence of the target API to a sterile Fill&Finish of a Drug Product. | Swiss Biotech Center (SBC) – Your Micro-CDMO Partner for Early-Stage Innovation The Swiss Biotech Center (SBC) is a specialized micro-CDMO located in Monthey (Valais), Switzerland, offering tailored development and manufacturing services to biotech start-ups, emerging companies, and research organizations. Designed to support the early stages of drug development, SBC helps bridge the gap between discovery and clinical readiness—particularly for complex, high-value molecules and innovative therapeutic approaches. With its flexible, GMP-compatible infrastructure and experienced multidisciplinary team, SBC provides a unique platform for accelerating biotech innovation in a controlled, collaborative, and efficient environment. Tailored CDMO Services for Start-Ups and Early Programs SBC focuses on supporting projects that require agility, customization, and scientific depth. Its services span the entire early development value chain: Process development and scale-up for biologics, cell and gene therapies, vaccines, and novel modalities Small-scale GMP manufacturing for preclinical and Phase I/II clinical trials Technology transfer and process optimization Analytical development and quality control Project-specific regulatory support and documentation SBC’s plug-and-play facilities are ideal for start-ups and smaller companies needing rapid access to high-quality infrastructure without the burden of large-scale operations. A Strategic Partner in Translational Development SBC is much more than a service provider—it acts as a development partner, helping innovators de-risk their technologies and move efficiently toward clinical and industrial milestones. Its integrated model fosters close collaboration, flexibility in project execution, and rapid iteration cycles essential for early-stage biotech ventures. By offering personalized guidance, SBC enables clients to navigate technical, operational, and regulatory challenges while maintaining full control over their intellectual property and strategic direction. Embedded in a Thriving Swiss Biotech Ecosystem Located in the BioArk Monthey innovation campus, SBC is part of a vibrant regional ecosystem that includes biotech companies, academic partners, and specialized service providers. The Valais region is a recognized center of excellence in life sciences and biomanufacturing, offering a strong talent base and high-performance infrastructure. This strategic setting provides SBC clients with valuable networking opportunities, access to public-private initiatives, and a collaborative environment ideal for scaling biotech innovation.
Stämm
Stämm is an international biotechnology company that is revolutionizing the way biomanufacturing is done. Founded in 2016, it’s now based in the United States and has offices and labs in Argentina and Switzerland. The company offers advanced solutions for automated, continuous, and improved biologics & cell therapies production with a wide range of solutions that stem from their core solution, the Bioprocessor, to cell line development and an AI transomics platform. Stämm’s mission is to make bioprocesses easy, scalable, sustainable and repeatable inspired by nature’s solutions, unleashing the full potential of biotechnology and thus freeing their partners to focus on the disruptive discoveries that make an impact in people’s lives. The company is committed to providing the best possible solutions to accelerate life-changing therapies through flexible, future-ready facilities that meet the evolving needs of its clients and improve global health. Products & Services Stämm’s products and services are structured in three segments: 1. Biomanufacturing: Stämm’s core solution is a continuous, bubble-free Bioprocessor, a biomanufacturing platform with a novel 3D printed bioreactor that enhances yields, reduces costs, and minimizes footprint and energy consumption. Stämm’s approach enables a scalable,energy-efficient solution that provides an ideal cell growth environment. 2. Bio AI: Stämm is developing a transomics platform that leverages in-silico methods through their Multi-omic Network Atlas (MoNA™) allowing to map the biomolecular behaviour of cells with its experimental ambient conditions. With MoNA, biotechnologists and molecular biologists will be able to reduce the uncertainty and risk during wet-lab assay design, execution and interpretation. Therefore achieving high precision biomolecular decision-making. 3.Bioenegineering: Stämm is developing state-of-the-art devices for Cell Line Development with automated cell engineering, clone outgrowth & screening for production of biologics. This is being done through a Bioengineering Platform, an engineering and sorting platform powered by a high-throughput automated system to streamline your workflow and a Clone Selection Platform, a specialized solution that automates clone selection and screening, monitoring the process to optimize your pipeline. Stämm’s is committed to providing a bio-innovative perspective capable of tackling the entire biomanufacturing pipeline
REM Analytics
Technology platform for microbiome testing, with applications in vaginal microbiome, gut bifidobacterium, soil and much else. We provide test development, sample analysis and laboratory instruments + consumables to run our tests in-house.
Orio Therapeutics
Orio Therapeutics originates from the research work of its two co-founders in the field of regenerative medicine and protein engineering. The company is based on a patented technology they developed at Monash University, Australia, allowing them to integrate a “built-in” delivery system for any therapeutic protein. Based on the Swiss roots of the co-founders and the Australian origin of the technology, Orio Therapeutics is taking this opportunity to develop its activities in Monthey and Melbourne. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients (STEMI) . | Orio Therapeutics is a biotechnology company dedicated to unlocking the power of protein engineering and targeted drug delivery for the creation of next-generation regenerative medicines. The company’s innovative platform addresses fundamental limitations in current treatments, promising increased effectiveness and reduced side effects across various therapeutic areas. Orio Therapeutics operates with headquarters at the BioArk Technological Site in Monthey, Valais, Switzerland, and a secondary location at Monash University in Melbourne, Australia. | Orio Therapeutics is a biotechnology company focused on revolutionizing protein therapeutics through its innovative drug delivery platform. Our core technology, originating from research at Monash University, allows us to engineer virtually any therapeutic protein with a “built-in” system that binds to the extracellular matrix (ECM). This localized delivery approach minimizes drug diffusion, enabling the use of significantly lower doses, enhancing efficacy, improving safety, and reducing costs. While we are initially focused on developing OTX-001 for myocardial infarction, we are actively exploring the broad applicability of our ECM-binding technology to other therapeutic areas where targeted protein delivery can provide significant clinical benefits.
Novochizol SA
Novochizol SA researches and develops applications of NOVOCHIZOL™ , a fist-in-class technology that transforms individual chitosan molecules into well-defined nanoparticles. Novochizol improves the characteristics of ordinary chitosans and yields materials with new properties for applications in pharma, medtech, biotech, agriculture, and other industries. As a biocompatible biopolymer, NOVOCHIZOL™ improves the interfacing of different materials with living tissues. In in vitro diagnostics, Novochizol™ enables better nucleic acid purification and improves the specificity and sensitivity of PCR and immunological tests. As an excipient, Novochizol™ can be used to formulate small molecules, nucleic acids, peptides, proteins, viruses and cells. Novochizol™ formulations are strongly bioadherent, enabling sustained release of active ingredients, deep tissue penetration and intracellular targeting. NOVOCHIZOL™ is the first chitosan-based nanoparticle compatible with pharma standards. Its starting material is a new type of biotech chitosan, manufactured by Alpha Chitin, a producer of precision chitosans with precise and reproducible physico-chemical characteristics, guaranteed traceability and batch-to-batch reproducibility. NOVOCHIZOL™ synthesis is also extremely well-defined: it is based on monomolecular, intramolecular cross-linking, in which a single linear molecule of chitosan is folded into a single nanoparticle. The outcome of the reactionis fully defined by the characteristics of the starting chitosan and the amount of the added cross-linking agent. In other words, the number of variables during synthesis is reduced to a strict minimum, yielding highly uniform particles that are easy to customize, to characterize, and to reproduce, in compliance with the regulatory requitements. NOVOCHIZOL™ meets all the criteria for Safe-by-Desing manufacturing. As a drug delivery system, NOVOCHIZOL™ allows rapid formulation of all classes of active pharmaceutical ingredients: small molecules, peptides, nucleic acids, proteins, polysaccharides, viruses and mammalian cells. Different dosage forms are possible: injectables, topicals, aerosols, and implant coatings. The resulting formulations are strongly bioaadhesive and mucoadhesive, enabling localized delivery of APIs at the sire of administration, without systemic distribution. NOVOCHIZOL™ formulations ensure protection of fragile APIs against biological degradation and have customizable release properties. Importantly, they can be endocytosed at the site of administration in a receptor-independent manner, making it possible for APIs to reach new, intracelluar therapeutic targets. NOVOCHIZOL™ has an excellent safety profile as a polysaccharide that is fully biocompatible and biodegradable. NOVOCHIZOL™ business model is based on two, convergent strategies: bona fide drug development and excipient registration and out-licensing of Novochizol™ as a drug delivery system. We are currently focusing on the development of new nanomedicines in immuno-concology (intra-tumoral delivery of therapetucally-effective doses of native and engineered cytokines), in respiratory diseases (inhalable drug delivery systems), and in cosmetic surgery and osteoarthritis (development of long-lasting formulations of hyaluronic acid as dermo fillers and for joint repair). We are leveraging on these early-stage drug development projects to reach regulatory qualification of Novochizol™ for pharmaceutical use in 2024) and to develop a rapid formulation testing platform for any API candidate that needs to be delivered to specific tissues or organs, avoiding systemic distribution. NOVOCHIZOL™ aims to become the first chitosan nanoparticle approved for pharmaceutical use
Ninsun Biotech
Ninsun Biotech is a start-up based in Valais at BioArk. It operates in the field of oncology and is revolutionising the marking of cancer stem cells by offering, for the first time, a specific biomarker for several cancers, including lung, breast and colon. Current technologies rely on the use of a combination of non-specific markers, so Ninsun Biotech is breaking new ground with its patented technology, offering new prospects in terms of diagnosis, monitoring (companion tests) and, ultimately, individualised treatment for patients. Ninsun Biotech’s stem cell marking kits are also perfectly compatible with the current clinical chain of patient management.
ImmunSkills SA
ImmunSkills is a Swiss-based biotech start up with a mission to revolutionize cancer treatment. Our platform technology involves genetically modifying allogeneic natural killer cells to resist the tumor microenvironment (TME) and improve therapeutic outcomes in solid tumor patients. Today we are aiming at being a Contract Development and Manufacturing Organization (CDMO) offering a one-stop-shop solution for companies looking to develop new cell-based therapies targeting solid cancers. We plan to collaborate with our clients, introducing their CAR constructs into our cells and producing them at large scales. This will help our clients to de-risk their product development and accelerate their time to clinics or market.. To summarize, our clients only need to be sure about their CAR (i.e.the client’s CAR construct recognizes the tumor-specific antigen) and the rest in under ImmunSkills responsibilities Our platform technology has already shown promising results in-vitro. In order to finalize our proof of concept we intend to use a CAR-construct that has been developed at the University of Applied Sciences and targets pancreatic cancer cells. Following an eventual positive outcome of the project we may produce enough immune cells using our platform technology to initiate first studies in animal models. | ImmunSkills SA, located in Switzerland, is currently developing a cutting-edge platform for the manufacture of allogeneic cell therapies, specifically tailored for solid tumors. Our core innovation revolves around enhancing natural killer (NK) cells to withstand the hostile tumor microenvironment (TME) and to target cancer cells more effectively. These cells are engineered to incorporate chimeric antigen receptors (CARs), allowing for precise targeting of tumor-specific antigens. As a contract development and manufacturing organization (CDMO), we are focused on streamlining the development process for our clients, from initial cell line development to scalable, GMP-compliant manufacturing. Our upcoming facilities are designed to support rapid production scaling and to help biopharmaceutical companies and startups efficiently navigate the path from lab to clinical trials, optimizing both time and costs
ExcellGene
ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. Visit our booth #1743 to learn more about our services and products, and go to www.excellgene.com for additional information or to get in touch. | ExcellGene is a leading biotechnology company specializing in developing and producing high-quality recombinant proteins and monoclonal antibodies, with expertise in CHO and HEK-293 cell lines. With over 20 years of experience in the field, our dedicated team of experts ensures reliable, timely, and efficient customized solutions meeting the highest quality standards for a wide range of research, diagnostic, and therapeutic applications. | Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.
Ceidos
Bioproduction is complex particularly during cell expansion in bioreactors. Current methods to assess the viability, density and shape of mammalian cells are highly manual and require recurrent sampling. The C-Netics enables non-destructive and label-free analysis in real time. It works coupled to a dedicated single use kit that integrates an analysis cassette with high-end microelectronic sensors. The monitoring can then be run automatically during the entire duration of the cell culture.This allows the detection of anomalies in real-time and can also be used to quickly optimize a process development. | Ceidos offers an automatic laboratory device that improves the biopharmaceutical production process. Faced with the challenge of slow, manual control of cell cultures, Ceidos introduces the C-Netics, a sophisticated device compatible with most bioreactors. It enables automated, real-time cell culture analysis with a single-use kit, increasing efficiency, reducing contamination and guaranteeing high-quality results, revolutionizing laboratory work and setting new standards in the field of biotechnology. Ceidos SA is a pioneering biotechnology company based in Monthey, Switzerland and founded in 2019. Specializing in the development of innovative solutions for the biopharmaceutical industry, Ceidos is expert in advanced technologies such as microscopy, microelectronics, and machine learning allowing the development of breakthrough bioprocessing devices. | Ceidos aims to revolutionize biopharmaceutical production with C-Netics, an advanced system for real-time, non-destructive cell culture monitoring. By integrating microscopy, dielectrophoresis, and AI-driven analysis, C-Netics ensures precise control of cell viability, density, and culture conditions. Unlike traditional methods, it connects directly to bioreactors, minimizing contamination risks and reducing manual interventions. Ceidos collaborates with industry leaders and CMOs/CDMOs to optimize bioprocesses, enhance efficiency, and improve the scalability of advanced therapies like CAR-T and monoclonal antibodies.
Bolliger & Mabillard Inc.
Bolliger & Mabillard is specialized in the delivery of custom-designed roller coasters. Each ride is conceived to meet the customer’s specific requirements. Reliable, unique, smooth and popular roller coasters as well as quality services and on-time delivery have built B&M’s reputation throughout the years. B&M products include the Flying Coaster, Dive Coaster, Wing Coaster, Hyper Coaster, Stand-Up Coaster, Inverted Coaster, Floorless Coaster, Sitting Coaster, Launch Coaster and Family Coaster. | Bolliger & Mabillard is specialized in the delivery of custom-designed roller coasters. Each ride is conceived to meet the customer’s specific requirements. Reliable, unique, smooth and popular roller coasters as well as quality services and on-time delivery have built B&M’s reputation throughout the years. B&M products include the Flying Coaster, Dive Coaster, Wing Coaster, Hyper Coaster, Surf Coaster, Inverted Coaster, Floorless Coaster, Sitting Coaster, Launch Coaster and Family Coaster.